Dipeptidyl-Peptidase IV Inhibitor
SGLT2 inhibitors associated with reduced AF risk in older patients with type 2 diabetes
SGLT2 inhibition in older patients with type 2 diabetes was associated with lower risk for incident atrial fibrillation compared with dipeptidyl peptidase IV inhibition or GLP-1 receptor agonist treatment, researchers reported.
SGLT2 inhibitors may lower risk for adverse renal outcomes vs. DPP-IV inhibitors
The use of SGLT2 inhibitors with type 2 diabetes is associated with lower risks for end-stage renal disease and acute renal failure compared with DPP-IV inhibitor use, according to study findings from Hong Kong.
Fracture risks, benefits vary with different diabetes drugs
Clinicians should be cautious when prescribing certain antihyperglycemic agents for people with type 2 diabetes at risk for fracture, particularly when a patient is older with long disease duration or complications, according to a speaker.
One-fifth of COVID-19 patients with diabetes die within 28 days of hospitalization
New data from the CORONADO study show that 20% of people with diabetes hospitalized with COVID-19 die within 28 days of admission, whereas half are discharged in that same time span.
Sitagliptin linked to lower mortality rate in adults with type 2 diabetes, COVID-19
Adults with type 2 diabetes who were hospitalized with COVID-19 in northern Italy had a lower mortality rate and better health outcomes when treated with the DPP-IV inhibitor sitagliptin, according to study data published in Diabetes Care.
SGLT2 inhibitors triple DKA risk compared with DPP-IV inhibitors
SGLT2 inhibitor use is associated with an almost threefold increased risk for diabetic ketoacidosis compared with use of DPP-IV inhibitors, according to findings published in Annals of Internal Medicine.
'Insufficient evidence' to recommend DPP-IV inhibitor treatment in type 2 diabetes with COVID-19
Insulin — not DPP-IV inhibitors or GLP-1 receptor agonists — should be the agent of choice for the management of severely ill patients with diabetes and coronavirus infections; this position is supported by extensive historical experience and the increased adoption of continuous glucose monitoring, according to a literature review published in Endocrine Reviews.
Many adults discontinue DPP-IV inhibitor therapy after initiating insulin
More than half of adults with type 2 diabetes prescribed DPP-IV inhibitor therapy discontinued the medications within 1 year of initiating insulin, according to findings from a U.S. health claims database analysis.
Risk for autoimmune skin condition may be elevated by DPP-IV use
The skin condition bullous pemphigoid may be more likely to develop in adults with type 2 diabetes who use DPP-IV inhibitors vs. those who do not use the medication, especially if they also use spironolactone or have dementia, according to findings published in the Journal of Diabetes and its Complications.
Diabetes more effectively treated with immediate sitagliptin, metformin combination therapy
Insulin is needed less frequently and HbA1c is lowered more robustly when adults with type 2 diabetes do not delay combination therapy but begin treatment by taking sitagliptin and metformin together, according to findings published in Diabetic Medicine.